PureTech Health earnings date
PureTech Health (0VQ) Q2 2026 Earnings Report
DE:0VQ Q2 2026 EPS Results
- Actual EPS
- EUR 0.24
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 0.22
DE:0VQ Q2 2026 Revenue Results
- Actual Revenue
- EUR 3.12M
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- +85.24%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 09/22/2026
- Time
- Before Open
- Conference Call
- Tuesday, September 22, 2026
PureTech Health's next earnings date is estimated for April 29, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call was predominantly positive, with management highlighting major portfolio milestones, external financing, Seaport's IPO, Celea's Phase III launch, Gallop's FDA Fast Track designation, a cash runway extending at least through the end of 2028, lower expected future cash burn and a growing innovation pipeline. The main negatives were the year-to-date cash decline, higher first-half operating expenses, the material downgrade in estimated future Cobenfy proceeds, Celea's expected need for additional financing and Gallop's dependence on external financing before its Phase II trial can begin.
PureTech reiterated an operational runway at least through the end of 2028, excluding inflows from potential future monetization events and assuming full deployment of the additional $70 million reserved for potential future investments in Celea; it expects go-forward cash burn, including overhead and innovation spend, to be somewhere between $30 million and $40 million a year, compared with the roughly $90 million a year cash burn when later-stage clinical programs were run internally. Gallop intends to complete external financing by the first half of next year, initiate STRIDE-MDS following receipt of external capital, and the approximately 125-patient trial is projected, on the more conservative side, to take probably somewhat under 3 years to complete, with the actual time line potentially more around 30 months or 33 months; PureTech aims to advance at least 3 opportunities to the concept stage each year, is currently running ahead of that, and expects to share additional detail in the first half of 2027.
- Strong Strategic Execution Across PortfolioManagement stated that PureTech made significant progress in 2026 and meaningfully executed against its refined strategy, including Seaport's NASDAQ IPO, Celea's external financing and Phase III initiation, Gallop's Fast Track designation, continued potential future Cobenfy economics, and advancement of the innovation engine.
- Seaport Therapeutics IPO and Portfolio ValueSeaport Therapeutics successfully completed an oversubscribed IPO on NASDAQ in May. Management stated that the IPO raised $260 million, while the detailed portfolio discussion referred to $250 million in gross proceeds. PureTech retains a 31.2% equity stake valued at approximately $360 million as of September 18, 2026, along with royalty and milestone rights.
- Celea Secures $180 Million and Begins Phase IIICelea Therapeutics secured $180 million from leading health care investors and immediately initiated the global Phase III SURPASS-IPF trial for deupirfenidone in idiopathic pulmonary fibrosis. PureTech retains a 35.4% equity interest and long-term economics through royalties, milestones and sublicense income rights.
- Gallop Receives FDA Fast Track DesignationGallop Oncology completed its end-of-Phase I meeting with the FDA and received Fast Track designation for LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome. Management said the designation validates the potential and active-drug profile of LYT-200.
- Positive LYT-200 Clinical FoundationManagement stated that positive Phase Ib results established a compelling clinical foundation for LYT-200, including compelling clinical efficacy and a consistent safety profile in high-risk MDS patients who had relapsed or become refractory after prior HMA treatment.
- STRIDE-MDS Phase II Trial Design FinalizedThe randomized, double-blinded, placebo-controlled STRIDE-MDS Phase II trial is planned to enroll approximately 125 patients, randomized 2:2:1 across LYT-200 at 12 milligrams per kilogram plus an HMA, LYT-200 at 7.5 milligrams per kilogram plus an HMA, or placebo plus an HMA. The trial will assess complete and partial response rates and support dose selection under the FDA's Project Optimus framework.
- Mutation-Agnostic Development Approach Accepted by FDAThe FDA accepted Gallop's mutation-agnostic approach and did not require biomarker selection. Management said there are currently no plans for biomarker selection in the STRIDE-MDS study.
- PureTech Maintains Full Ownership of GallopPureTech currently owns 100% of Gallop Oncology and intends to leverage external capital before initiating the Phase II STRIDE-MDS trial. The targeted financing is intended to support Gallop through the trial readout.
- Capital-Efficient Hub-and-Spoke ModelManagement described a model in which programs are generated and derisked internally before being scaled through founded entities or spoke companies backed by external capital. The approach is intended to preserve PureTech's balance sheet while retaining equity, royalties and milestone economics.
- Track Record of Approved Therapeutics and Value CreationPureTech stated that its model has produced 3 FDA-approved therapeutics, including Cobenfy, and has generated sufficient evergreen capital through opportunistic monetization of founded entities without the need for dilutive raises at the PureTech level.
- Significant Historical Cobenfy EconomicsThrough Karuna and Cobenfy economics, PureTech has generated more than $1 billion. PureTech also retains potential Cobenfy-related royalty and milestone payments following Bristol Myers Squibb's acquisition of Karuna Therapeutics.
- Operational Runway Extends Through 2028PureTech ended June 2026 with approximately $220 million of cash, cash equivalents and short-term investments and reiterated that its operational runway extends at least through the end of 2028. The runway excludes inflows from potential future monetization events and assumes full deployment of the additional $70 million reserved for potential future investments in Celea.
- Expected Reduction in PureTech Operating ExpensesManagement stated that future deupirfenidone expenses have shifted to Celea and that PureTech expects a significant reduction in overall operating expenses moving forward. Go-forward cash burn, including overhead and innovation spending, is expected to be between $30 million and $40 million per year, compared with roughly $90 million per year when later-stage clinical programs were run internally.
- Disciplined Capital Allocation and Potential Shareholder ReturnsPureTech plans to prioritize maintaining an appropriate operational runway, selectively deploying capital into compelling risk-adjusted opportunities and returning capital to shareholders. Management said the company does not want to hold too much cash and is considering the relative cost of capital across equity, pharma partnerships and other funding structures.
- Focused LIFE Innovation FrameworkPureTech's innovation strategy is centered on its LIFE model, or launching innovation from existing pharmacology. The framework targets clinically validated mechanisms or molecules whose potential was constrained by limitations unrelated to efficacy, then seeks to preserve efficacy while overcoming those limitations through focused proof-of-concept experiments and proprietary intellectual property.
- Innovation Pipeline Running Ahead of TargetPureTech aims to advance at least 3 opportunities to the concept stage each year. Management stated that the company is currently running ahead of that target and has been pleasantly surprised by both the quantity and quality of opportunities.
- Continued Focus on Small Molecules and CNSThe innovation pipeline continues to focus on small molecule-based therapeutics and CNS opportunities, particularly neuropsychiatry, where PureTech has had success with Cobenfy and Seaport. Management also stated that the model remains somewhat indication-agnostic and could be applied outside CNS.
- Planned Innovation Updates in 2027Management expects to share additional detail on innovation progress in the first half of 2027. The programs disclosed then may still have some preclinical work remaining, but PureTech expects to have completed key derisking experiments and to have a high degree of confidence in their prospects.
- Gallop Financing Options Remain BroadPureTech is evaluating a range of funding options for Gallop, including equity, pharma partnerships and other structures. Management said the indication and available data are exciting enough to open different possibilities and that the company aims to complete financing by the first half of 2027.
DE:0VQ Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 29, 2027 | 2026 (Q4) | ―- | -0.24 | ― | ― |
| Sep 22, 2026 | 2026 (Q2) | ―0.24 | -0.22 | 208.42% (+0.47) | |
| Apr 29, 2026 | 2025 (Q4) | -0.17-0.24 | 0.42 | -156.11% (-0.66) | |
| Aug 28, 2025 | 2025 (Q2) | -0.18-0.17 | -0.13 | -26.67% (-0.04) | |
| Apr 30, 2025 | 2024 (Q4) | -0.250.32 | -0.13 | 340.00% (+0.45) | |
| Aug 28, 2024 | 2024 (Q2) | -0.27-0.13 | -0.08 | -66.67% (-0.05) | |
| Apr 25, 2024 | 2023 (Q4) | -0.29-0.13 | -0.07 | -92.31% (-0.06) | |
| Aug 29, 2023 | 2023 (Q2) | -0.00-0.08 | -0.09 | 10.00% (+0.01) | |
| Apr 28, 2023 | 2022 (Q4) | 0.03-0.07 | 0.04 | -256.00% (-0.11) | |
| Aug 25, 2022 | 2022 (Q2) | -0.24-0.09 | -0.23 | 61.54% (+0.14) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

